CoChat
Sign Up
Cited by 229Peroxisome Proliferator-Activated ReceptorsBreast Cancer Treatment StudiesCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study

Burstein, Harold J., Demetri, George D., Mueller, Elisabetta, Sarraf, Pasha, Spiegelman, Bruce M., Winer, Eric P.·2003·Breast Cancer Research and Treatment
DOI 10.1023/a:1024038127156
Open this paper in CoChat — free account

Abstract

Purpose To evaluate the therapeutic effects of the peroxisome proliferator-activated receptor (PPAR) gamma activating ligand, troglitazone, in patients with refractory metastatic breast cancer.Experimental design Patients with advanced breast cancer refractory to at least one chemotherapy regimen (ER negative tumors) or two hormonal regimens (ER positive tumors) were treated with troglitazone at 800 mg p.o. QD until disease progression, to determine the percentage of patients free of progression at 6 months. Tumor response, toxicity, and changes in serum tumor markers (CEA, CA27.29) that might reflect alteration in tumor differentiation, were also examined.Results Twenty-two patients were enrolled before suspension of protocol accrual and treatment when troglitazone was withdrawn from commercial availability following FDA warnings on hepatic toxicity. No objective responses (CR or PR) were observed; only three patients had SD at 8 weeks. Patients came off study for PD (16), DLT (1), FDA withdrawal (2), or other (3) reasons. No patients took troglitazone for more than 20 weeks; all had experienced disease progression or began other systemic therapy within 6 months. All patients with elevated serum tumor markers (CEA and CA27.29) at baseline had rising tumor markers within 8 weeks.Conclusions While clinical trials among different patient populations might uncover subtle effects on tumor differentiation, PPARgamma activation by troglitazone has little apparent clinical value among patients with treatment-refractory metastatic breast cancer.

Overview

Integrity signals

Registry

Crossref · 10.1023/a:1024038127156

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Only a few clinical trials of TZDs for cancer treatment have been conducted, and results have largely been negative.

    “Only a few clinical trials of TZDs for cancer treatment have been conducted, and results have largely been negative (108).”

    From Diabetes and Cancer (2010) · cites this paper as [108]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Demetri GD, Spiegelman B, Fletcher CD et al.: Differentiation of liposarcomas in patients treated with PPAR γ ligand troglitazone: documentation of biological activity in myxoid/ round cell and pleomorphic subtypes. Proc AmSoc Clin Oncol 18: 535a, 1999 (abstract 2064)

Cited by

Sorted by citations

Related

Metadata

Authors
Burstein, H. J., Demetri, G. D., Mueller, E., Sarraf, P., Spiegelman, B. M., & Winer, E. P.
Affiliations
  • Dana-Farber Cancer Institute (US)
  • Brigham and Women's Hospital (US)
ORCID
Venue
Breast Cancer Research and Treatment
Publisher
Springer Science and Business Media LLC
Published
2003-06
Volume
79
Issue
3
Pages
391-397
ISSN
  • 0167-6806 (ISSN-L)
  • 1573-7217
DOI
10.1023/a:1024038127156
OpenAlex
W1968980738
Cited by
228
References
21
Citations by year
2026: 2 · 2025: 1 · 2024: 5 · 2023: 4 · 2022: 4 · 2021: 14 · 2020: 5 · 2019: 7 · 2018: 13 · 2017: 11 · 2016: 5 · 2015: 3 · 2014: 4 · 2013: 10 · 2012: 18
FWCI
4.25
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Breast Cancer Research and Treatment (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
troglitazone, PPARγ agonists, metastatic breast cancer, estrogen receptor-negative breast cancer, estrogen receptor-positive breast cancer, tumor markers, CEA, CA 27.29, tumor differentiation, drug toxicity, disease progression
MeSH terms
Troglitazone, Administration, Oral, Adult, Aged, Antineoplastic Agents, Breast Neoplasms, Chromans, Female, Humans, Liver, Middle Aged, Neoplasm Invasiveness, Thiazoles, Treatment Outcome, Disease Progression, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review